EUVIMEDEUVIMED entdecken
Open Access

Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma

Kelsey S Lau-Min, Angela C Tramontano, Franklin Iheanacho, Thomas Adam Abrams, Christopher R Manz

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.51665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Kelsey S Lau-Min und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The treatment landscape for hepatocellular carcinoma (HCC) is rapidly evolving, with the approval of multiple systemic therapies for patients with advanced disease since 2017. However, ideal treatment sequencing approaches remain unknown, and data on clinical practice patterns are limited.

Objective

To evaluate current treatment patterns, sequencing, and survival outcomes among patients receiving systemic therapy for HCC. Design, Setting, and Participants This retrospective cohort study used data from a nationwide electronic health record (EHR)–derived database of more than 280 oncology practices at more than 800 US cancer clinics to assess adult patients who were treated with systemic therapy for HCC from January 1, 2011, to December 31, 2023. Exposure First-line systemic therapy type. Main Outcomes and Measures Overall survival (OS) was defined as the time from first-line systemic therapy initiation to death, last clinical activity, or the censor date of December 31, 2023. Progression-free survival (PFS) was defined as the time from first-line systemic therapy initiation to the earliest of EHR-documented disease progression, death, last clinical encounter, or the censor date.

Results

Among 4198 patients (median [IQR] age, 67 [61-74] years; 3353 [79.9%] male), sorafenib was the most common first-line systemic therapy until it was overtaken by atezolizumab-bevacizumab in 2020; durvalumab-tremelimumab also became a common first-line therapy in 2023. Of the full study cohort, 871 (20.7%) received second-line therapy. Median OS was 8.1 months (95% CI, 7.7-8.6 months) but was not significantly associated with first-line systemic therapy type. Median PFS was 3.9 months (95% CI, 3.7-4.0 months); first-line atezolizumab-bevacizumab (hazard ratio, 0.84; 95% CI, 0.71-0.99) was associated with improved PFS compared with sorafenib. Conclusions and relevance In this cohort study of patients treated with systemic therapy for HCC between 2011 and 2023, atezolizumab-bevacizumab and durvalumab-tremelimumab emerged as the most common first-line systemic therapies administered for HCC, but relatively few patients received second-line therapy. Additional research is needed to determine optimal treatment sequencing and increase the likelihood that patients may benefit from second-line systemic therapy options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsRetrospective StudiesElectronic Health RecordsProgression-Free SurvivalSorafenibBevacizumabAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalDisease ProgressionHumansMaleFemaleMiddle AgedAgedUnited States

Substanzen

SorafenibatezolizumabBevacizumabdurvalumabtremelimumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntibodies, MonoclonalProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Warren Alpert Medical School of Brown University, Providence, Rhode Island.

Zitieren

APA

Lau-Min, K. S., Tramontano, A. C., Iheanacho, F., Abrams, T. A., & Manz, C. R. (2025). Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.51665

Vancouver

Lau-Min KS, Tramontano AC, Iheanacho F, Abrams TA, Manz CR. Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.51665

BibTeX
@article{LauMin2025,
  author = {Lau-Min, Kelsey S and Tramontano, Angela C and Iheanacho, Franklin and Abrams, Thomas Adam and Manz, Christopher R},
  title = {Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.51665}
}
Kostenlos starten →